Wednesday, November 24, 2021
Home news Novel Drug Proven Effective Against Mutated Lung Cancer

Novel Drug Proven Effective Against Mutated Lung Cancer

The RAS gene family is among the most frequently mutated in human cancers, with one member of the group, KRAS, the most commonly occurring mutant in solid tumors and has remained

for decades.

‘Tumor size in lung cancer patients who have a specific genetic error in the KRAS gene is reduced by a novel KRASG12C inhibitor drug – Sotorasib. It specifically targets a building block (cysteine residue) in the gene that is present only in its inactive form that is, when mutated, thereby demonstrating significant benefit without any new safety concerns in patients.’


The KRAS gene encodes a protein switch that regulates growth but becomes “stuck in the “on” mode” when mutated, signaling cells to continually multiply in tumors. Among 200,000 patients who are diagnosed with lung cancer annually in the United States, this mutation is present in only about 13%.

The Drug – Sotorasib

The drug sotorasib is a KRASG12C inhibitor, developed by Amgen Inc., and was recently approved by the U.S. Food and Drug Administration for the treatment of adult patients with KRAS G12C-mutated NSCLC.

It was found that 37.1% of patients in the study saw their tumors shrink by at least 30%, termed an “objective response”, and 82% of those treated experienced some slowing of tumor growth or “disease control”. The average response duration of the drug was 11.1 months, for a median progression-free survival of 6.8 months.

The study also showed that 70% of patients had treatment-related adverse events, only about 20% had more severe events that required reduction of the dose of sotorasib. About 7% of patients had to stop treatment because of severe side effects. The most frequent of these were diarrhea, nausea, fatigue, and an increase in liver enzyme levels. There were no life-threatening side effects and no treatment-related deaths in the study.

Breakthrough Treatment for Mutated KRAS Cancer

Immunotherapy (PD1-inhibitors) or platinum-based combination chemotherapy was previously administered in all patients in the study. The currently available treatments have two and four months of median progression-free survival. Since those treatments were no longer effective to stop the regrowth of the cancers, the present study was conducted.

“The excitement surrounding this trial result is that sotorasib, just approved for clinical use, becomes the first targeted therapy for lung cancer patients with KRAS mutations. KRAS-targeted treatments, decades in the making, are urgently needed for these patients with limited therapeutic options,” says co-corresponding study author Vamsidhar Velcheti, MD, associate professor of Medicine at NYU Grossman of Medicine, and director of thoracic medical oncology at Perlmutter Cancer Center.

The drug targets a specific building block (cysteine residue) present only in the inactive form of KRAS that is, when the mutated. Thus the drug Sotorasib had significant benefit without any new safety concerns in patients with a specific form of KRAS mutant lung cancer.

The team also anticipates develop and test the efficacy of combination therapies using this drug. Also ongoing phase 3 CodeBreak 200 trial (NCT04303780), would compare the effect of sotorasib against chemotherapy, docetaxel.

Source: Medindia

Source link

RELATED ARTICLES

Shilpa Shetty Kundra performs as Kumar Sanu sings ‘Yeh Kaali Kaali Aankhein’ live on Super Dancer-Chapter 4 : Bollywood News

This weekend’s episode of Sony TV’s immensely loved dance show Super Dancer - Chapter 4, will see Kumar Sanu...

Construction deficiencies behind deadly Mexico City subway collapse, report finds

The investigation, carried out by Norwegian risk management firm DNV, suggests that deficient welding of metal studs, which apparently were not well connected...

Consumers Pay More for Ready-To-Eat Meals With Fewer Ingredients: Study

They are also more willing to fork out their hard-earned cash when they know their processed foods are made with a new technology that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Shilpa Shetty Kundra performs as Kumar Sanu sings ‘Yeh Kaali Kaali Aankhein’ live on Super Dancer-Chapter 4 : Bollywood News

This weekend’s episode of Sony TV’s immensely loved dance show Super Dancer - Chapter 4, will see Kumar Sanu...

Construction deficiencies behind deadly Mexico City subway collapse, report finds

The investigation, carried out by Norwegian risk management firm DNV, suggests that deficient welding of metal studs, which apparently were not well connected...

Consumers Pay More for Ready-To-Eat Meals With Fewer Ingredients: Study

They are also more willing to fork out their hard-earned cash when they know their processed foods are made with a new technology that...

Sonu Sood turns saviour for Mr. Telangana, Sushil Gaekwad : Bollywood News

Sonu Sood has become a life savior for 35-year-old, Hyderabad-based bodybuilder, Sushil Gaekwad. He had been diagnosed with Covid-19...

Recent Comments